stockrowSarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024.
- Revenue
- −4.51%
- EPS
- +46.0%
- Free cash flow
- +231.8%
- Total debt
- −17.2%
Quarter to September 2026, against a year earlier
Follow SRPT
Alert me
Sarepta Therapeutics, Inc. (SRPT) Revenue
Sarepta Therapeutics, Inc.'s revenue for fiscal 2025 was $2.2B, up 15.6% from $1.9B in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.0B. Over the past ten years it has ranged from $1.3M (fiscal 2015) to $2.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 10 consecutive fiscal years. Sarepta Therapeutics, Inc. ranks 15th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.2B | 15.58% |
| FY2024 | $1.9B | 52.97% |
| FY2023 | $1.2B | 33.26% |
| FY2022 | $933.0M | 32.93% |
| FY2021 | $701.9M | 29.96% |
| FY2020 | $540.1M | 41.82% |
| FY2019 | $380.8M | 26.51% |
| FY2018 | $301.0M | 94.74% |
| FY2017 | $154.6M | 2,751.58% |
| FY2016 | $5.4M | 332.64% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $381.4M | (4.96%) |
| Jun 2026 | $401.3M | (45.09%) |
| Mar 2026 | $730.8M | 64.99% |
| Dec 2025 | $442.9M | 10.91% |
| 35 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| SRPT Sarepta Therapeutics, Inc. | $2.0B |
| HRMY Harmony Biosciences Holdings, Inc. compare | $989.4M |
| VIR Vir Biotechnology, Inc. compare | $302.8M |
| MRVI Maravai LifeSciences Holdings, Inc. compare | $213.0M |
| MESO Mesoblast Limited compare | $7.5M |
| TRVI Trevi Therapeutics, Inc. compare | — |
| MAZE Maze Therapeutics, Inc. compare | — |
| TRAX First Tracks Biotherapeutics, Inc. compare | — |
| REPL Replimune Group, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item